Amid global market volatility, TipRanks offers valuable tools to guide investors. One of the most powerful is the Smart Score, which assigns a ranking of one to ten to stocks and highlights their potential to outperform the broader market. Using this tool, we have identified three standout stocks: Daqo New Energy (DQ), Trimble (TRMB), and Tango Therapeutics (TNGX). Each of these has earned a top Smart Score and a Strong Buy rating from Wall Street analysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The TipRanks’ Smart Score rates the stocks on a scale from 1 to 10, with 10 being the highest. The score is based on eight key market factors, including Wall Street analyst ratings, insider transactions, financial blogger opinions, and more. Additionally, the Top Smart Score Stocks list offers a comprehensive selection of stocks rated a perfect 10, along with advanced filtering options.
Let’s dive into the details.
What Is the Stock Forecast for Daqo New Energy?
Daqo New Energy is a Chinese manufacturer of high-purity polysilicon, a key material for solar photovoltaic (PV) products. Year-to-date, DQ stock has gained over 30%.
Looking ahead, Wall Street analysts remain bullish on its upside potential. Out of five analysts covering DQ stock, four rate it as a Buy. Meanwhile, Daqo’s average stock price target of $31.20 suggests a potential upside of 22% from current levels.
Is Trimble Stock a Buy?
Trimble Inc. is a U.S.-based technology company specializing in advanced positioning, modeling, and data analytics solutions.
Year-to-date, TRMB stock has gained 9%. Wall Street analysts remain bullish, with all eight covering analysts giving it a Buy rating. According to TipRanks, Trimble’s stock has a price target of $96.29, implying 25% upside from current levels.
Is Tango Therapeutics a Good Stock to Buy?
Tango Therapeutics is a clinical-stage biotechnology company focused on precision oncology. So far in 2025, TNGX stock has gained 150%.
TNGX stock carries a Strong Buy rating, with five Buys assigned in the past three months. The average price target of Tango Therapeutics is $11.40, which implies a potential upside of 48%.
